BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38859863)

  • 41. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
    Ghaneh P; Palmer D; Cicconi S; Jackson R; Halloran CM; Rawcliffe C; Sripadam R; Mukherjee S; Soonawalla Z; Wadsley J; Al-Mukhtar A; Dickson E; Graham J; Jiao L; Wasan HS; Tait IS; Prachalias A; Ross P; Valle JW; O'Reilly DA; Al-Sarireh B; Gwynne S; Ahmed I; Connolly K; Yim KL; Cunningham D; Armstrong T; Archer C; Roberts K; Ma YT; Springfeld C; Tjaden C; Hackert T; Büchler MW; Neoptolemos JP;
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):157-168. PubMed ID: 36521500
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.
    Khushman M; Dempsey N; Maldonado JC; Loaiza-Bonilla A; Velez M; Carcas L; Dammrich D; Hurtado-Cordovi J; Parajuli R; Pollack T; Harwood AP; Macintyre J; Tzeng CW; Merchan JR; Restrepo MH; Akunyili II; Ribeiro A; Narayanan G; Portelance L; Sleeman D; Levi JU; Lima CM; Hosein PJ
    Pancreatology; 2015; 15(6):667-73. PubMed ID: 26412296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between neoadjuvant chemoradiation and survival for patients with locally advanced rectal cancer.
    Sun Z; Adam MA; Kim J; Turner MC; Fisher DA; Choudhury KR; Czito BG; Migaly J; Mantyh CR
    Colorectal Dis; 2017 Dec; 19(12):1058-1066. PubMed ID: 28586509
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
    Park JK; Ryu JK; Lee JK; Yoon WJ; Lee SH; Kim YT; Yoon YB
    Pancreas; 2006 Nov; 33(4):397-402. PubMed ID: 17079946
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma.
    Kim YI; Park JW; Kim BH; Woo SM; Kim TH; Koh YH; Lee WJ; Kim CM
    Radiat Oncol; 2013 Dec; 8():292. PubMed ID: 24359879
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of neoadjuvant concurrent chemoradiation in locally advanced unresectable pancreatic cancer: a feasibility study at tertiary care centre.
    Kapoor R; Khosla D; Gupta R; Bahl A; Shukla AK; Sharma SC
    Indian J Cancer; 2014; 51(2):176-9. PubMed ID: 25104204
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB-IVA cervical cancer: study protocol for a randomized controlled trial.
    Li J; Liu H; Li Y; Li J; Shen L; Long W; Yang C; Xu H; Xi W; Cai R; Feng W
    Trials; 2022 Jan; 23(1):29. PubMed ID: 35012634
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Survival Benefit of Induction Chemotherapy with Paclitaxel and Carboplatin Followed by Chemoradiation Versus Postoperative Treatment in Locally Advanced Gastric Cancer: A Retrospective Cohort Study.
    Azadeh P; Gholizadeh Pasha S; Yaghobi Joybari A; Abiar Z; Alahyari S; Taghizadeh-Hesary F
    J Gastrointest Cancer; 2024 Mar; 55(1):457-466. PubMed ID: 38010493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
    Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP
    Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
    Kong L; Zhang YW; Hu CS; Guo Y
    Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
    Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
    Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
    Nanda RH; El-Rayes B; Maithel SK; Landry J
    J Surg Oncol; 2015 Jun; 111(8):1028-34. PubMed ID: 26073887
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone.
    Huang EH; Liao Z; Cox JD; Guerrero TM; Chang JY; Jeter M; Borghero Y; Wei X; Fossella F; Herbst RS; Blumenschein GR; Moran C; Allen PK; Komaki R
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):779-85. PubMed ID: 17418967
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
    Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
    J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 56. Concurrent chemoradiotherapy with or without neoadjuvant chemotherapy in pediatric patients with stage III-IVa nasopharyngeal carcinoma: a real-world propensity score-matched cohort study.
    Jin YN; Ruan ZH; Cao WW; Yang L; Yao W; Pei XF; Zhang WJ; Marks T; Yao JJ; Xia LP
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11929-11940. PubMed ID: 37418058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adjuvant Chemotherapy After Preoperative Chemoradiation Improves Survival in Patients With Locally Advanced Rectal Cancer.
    Sun Z; Gilmore B; Adam MA; Kim J; Hsu SD; Migaly J; Mantyh CR
    Dis Colon Rectum; 2017 Oct; 60(10):1050-1056. PubMed ID: 28891848
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
    Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
    BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neoadjuvant Chemotherapy vs Chemoradiation Therapy Followed by Sleeve Resection for Resectable Lung Cancer.
    Jaradeh M; Vigneswaran WT; Raad W; Lubawski J; Freeman R; Abdelsattar ZM
    Ann Thorac Surg; 2022 Dec; 114(6):2041-2047. PubMed ID: 35351422
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer.
    Ma SJ; Prezzano KM; Hermann GM; Singh AK
    Radiat Oncol; 2018 Nov; 13(1):214. PubMed ID: 30400962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.